Technical Analysis for SLXN - Silexion Therapeutics Ltd.

Grade Last Price % Change Price Change
F 0.24 -17.97% -0.05
SLXN closed down 17.97 percent on Friday, November 1, 2024, on 50 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 12
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -17.97%
Wide Bands Range Expansion -17.97%
Oversold Stochastic Weakness -17.97%
Narrow Range Bar Range Contraction -17.69%

   Recent Intraday Alerts

Alert Time
Fell Below Lower Bollinger Band about 20 hours ago
Down 5% about 23 hours ago
Down 3% about 23 hours ago
Fell Below Previous Day's Low about 23 hours ago
Down 2 % about 23 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer.
Classification

Sector: Financial Services
Industry: Shell Companies
Keywords: Biotechnology Cancer Oncology Chemotherapy Pancreatic Cancer Oncogenes Solid Tumor Cancers Human Cancers Ras Gtpase Oncogene Locally Advanced Pancreatic Cancer

Is SLXN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.5576
52 Week Low 0.2322
Average Volume 3,356,238
200-Day Moving Average 8.27
50-Day Moving Average 0.71
20-Day Moving Average 0.32
10-Day Moving Average 0.31
Average True Range 0.10
RSI (14) 25.93
ADX 42.4
+DI 15.99
-DI 35.88
Chandelier Exit (Long, 3 ATRs) 0.25
Chandelier Exit (Short, 3 ATRs) 0.53
Upper Bollinger Bands 0.42
Lower Bollinger Band 0.23
Percent B (%b) 0.05
BandWidth 56.64
MACD Line -0.26
MACD Signal Line -0.35
MACD Histogram 0.0868
Fundamentals Value
Market Cap 936.54 Thousand
Num Shares 3.87 Million
EPS 0.11
Price-to-Earnings (P/E) Ratio 2.20
Price-to-Sales 71.53
Price-to-Book 13.58
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.34
Resistance 3 (R3) 0.34 0.32 0.32
Resistance 2 (R2) 0.32 0.30 0.32 0.32
Resistance 1 (R1) 0.28 0.28 0.27 0.27 0.31
Pivot Point 0.26 0.26 0.25 0.25 0.26
Support 1 (S1) 0.22 0.23 0.21 0.21 0.17
Support 2 (S2) 0.19 0.22 0.19 0.17
Support 3 (S3) 0.16 0.19 0.16
Support 4 (S4) 0.15